COMP <GO>
PHAT vs CRMD // EV/EBITDA & P/E VALUATION
Phathom Pharmaceuticals Inc. (NASDAQ) VS. CorMedix Inc. (NASDAQ) • 15-METRIC TALLY: PHAT 1
— CRMD 6
■ METRIC PARITY
LAST: $5.92 (+3.05%) • MKT CAP: $466.6M
valuation
—
LAST: $5.39 (-5.36%) • MKT CAP: $443.9M
valuation
3.0x
15-METRIC INSTITUTIONAL SIDE-BY-SIDE SCORECARD (PHAT VS. CRMD)
EMERALD CELL = QUANTITATIVE EDGE
| INSTITUTIONAL METRIC | PHAT | CRMD | SPREAD (A - B) | ADVANTAGE | DEDICATED URL |
|---|---|---|---|---|---|
| Gross Profit Margin | 87.10% | 88.50% | -1.40 | CRMD | /gross-margins <GO> |
| Return on Invested Capital (ROIC) | -35.00% | 45.50% | -80.50 | CRMD | /roic <GO> |
| EV/EBITDA & P/E Valuation ACTIVE | — | 3.0x | — | TIE | /valuation <GO> |
| Free Cash Flow Yield | — | — | — | TIE | /fcf-yield <GO> |
| Operating Margin | -60.00% | 48.20% | -108.20 | CRMD | /operating-margins <GO> |
| Net Profit Margin | -0.10% | 52.30% | -52.40 | CRMD | /net-margins <GO> |
| Revenue Growth (YoY) | 180.00% | 180.00% | 0.00 | TIE | /revenue-growth <GO> |
| Dividend Yield & FCF Payout Safety | 0.00% | 0.00% | 0.00 | TIE | /dividend-safety <GO> |
| Altman Z-Score & Debt/Equity | — | 1.81 | — | TIE | /balance-sheet <GO> |
| Piotroski F-Score Quality | 4/9 | 8/9 | -4.00 | CRMD | /piotroski-score <GO> |
| Options Implied Move & Put/Call Skew | — | — | — | TIE | /options-implied-move <GO> |
| RSI-14 & 200D SMA Momentum | 36.7 | 37.1 | -0.40 | CRMD | /rsi-technicals <GO> |
| 10Y Yield & FRED Macro Beta | — | — | — | TIE | /macro-sensitivity <GO> |
| Forward P/E Multiple | — | 3.5x | — | TIE | /forward-pe <GO> |
| Enterprise Scale & Market Cap | $466.6M | $443.9M | $22.7M | PHAT | /market-cap <GO> |
5-YEAR HISTORICAL XBRL REVENUE & MARGIN TRAJECTORY SEC FORM 10-K FY
| FISCAL YEAR | PHAT REV | CRMD REV | PHAT GROSS % | CRMD GROSS % | PHAT FCF | CRMD FCF |
|---|---|---|---|---|---|---|
| FY 2025 | $175.1M | $311.7M | 87.1% | 88.5% | -$167.0M | $172.8M |
| FY 2024 | $55.3M | $43.5M | 85.6% | 92.7% | -$266.9M | -$50.7M |
| FY 2023 | $682.0K | $137.1M | — | — | -$137.6M | -$38.4M |
FRED MACRO REGIME CORRELATION COMPARISON PEARSON r
PHAT // BETA —
CRMD // BETA —